{"entity":{"id":"ibt1116","kind":"drug","name":"IBT1116","aka":[],"tldr":"IBT1116 is an experimental off-the-shelf immune cell treatment from ImmuneBro Therapeutics for B-cell cancers, including after CAR-T relapse. It has not yet entered trials.","summary":"IBT1116 is the lead asset of ImmuneBro Therapeutics, an allogeneic engager T cell product at the IND-enabling stage for relapsed or refractory B-cell malignancies and relapse after CD19 CAR-T therapy, according to the company's website. No clinical data exist.","status":"preclinical","asOf":"2026-11-04","links":[{"label":"ImmuneBro Therapeutics","url":"https://www.immunebro.com/"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":["allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":["immunebro-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"IBT1116","modality":"Allogeneic engager T cell therapy","mechanism":"Healthy-donor T cells that also deliver a T cell engager, so they kill cancer cells directly and recruit the patient's own immune cells, without gene editing, as the developer describes.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ibt1116/","neighbours":{"technology":[{"id":"allogeneic-cell-therapy","kind":"technology","name":"Allogeneic (off-the-shelf) cell therapy","route":"/technologies/allogeneic-cell-therapy/"}],"company":[{"id":"immunebro-therapeutics","kind":"company","name":"ImmuneBro Therapeutics","route":"/companies/immunebro-therapeutics/"}]}}